- Home
- IONS vs GBCI Comparison
IONS vs GBCI Comparison
Compare IONS & GBCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- GBCI
- Stock Information
- Founded
- IONS 1989
- GBCI 1955
- Country
- IONS United States
- GBCI United States
- Employees
- IONS N/A
- GBCI N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- GBCI Major Banks
- Sector
- IONS Health Care
- GBCI Finance
- Exchange
- IONS Nasdaq
- GBCI Nasdaq
- Market Cap
- IONS 4.6B
- GBCI N/A
- IPO Year
- IONS 1991
- GBCI N/A
- Fundamental
- Price
- IONS $32.26
- GBCI $42.14
- Analyst Decision
- IONS Buy
- GBCI Hold
- Analyst Count
- IONS 18
- GBCI 4
- Target Price
- IONS $57.41
- GBCI $53.00
- AVG Volume (30 Days)
- IONS 1.7M
- GBCI 549.2K
- Earning Date
- IONS 04-30-2025
- GBCI 04-24-2025
- Dividend Yield
- IONS N/A
- GBCI 3.13%
- EPS Growth
- IONS N/A
- GBCI 7.02
- EPS
- IONS N/A
- GBCI 1.87
- Revenue
- IONS $717,253,000.00
- GBCI $827,816,000.00
- Revenue This Year
- IONS N/A
- GBCI $13.78
- Revenue Next Year
- IONS $27.39
- GBCI $14.77
- P/E Ratio
- IONS N/A
- GBCI $22.58
- Revenue Growth
- IONS N/A
- GBCI 8.47
- 52 Week Low
- IONS $23.95
- GBCI $34.48
- 52 Week High
- IONS $52.34
- GBCI $60.67
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- GBCI 52.73
- Support Level
- IONS $31.66
- GBCI $40.80
- Resistance Level
- IONS $33.98
- GBCI $42.69
- Average True Range (ATR)
- IONS 1.30
- GBCI 1.20
- MACD
- IONS 0.41
- GBCI 0.34
- Stochastic Oscillator
- IONS 68.84
- GBCI 82.78
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.